47 related articles for article (PubMed ID: 38614983)
1. Neoadjuvant Treatment for Borderline Resectable Pancreatic Ductal Adenocarcinoma.
Kaufmann B; Hartmann D; D'Haese JG; Stupakov P; Radenkovic D; Gloor B; Friess H
Dig Surg; 2019; 36(6):455-461. PubMed ID: 30408790
[TBL] [Abstract][Full Text] [Related]
2. Definition of a standard lymphadenectomy in surgery for pancreatic ductal adenocarcinoma: a consensus statement by the International Study Group on Pancreatic Surgery (ISGPS).
Tol JA; Gouma DJ; Bassi C; Dervenis C; Montorsi M; Adham M; Andrén-Sandberg A; Asbun HJ; Bockhorn M; Büchler MW; Conlon KC; Fernández-Cruz L; Fingerhut A; Friess H; Hartwig W; Izbicki JR; Lillemoe KD; Milicevic MN; Neoptolemos JP; Shrikhande SV; Vollmer CM; Yeo CJ; Charnley RM;
Surgery; 2014 Sep; 156(3):591-600. PubMed ID: 25061003
[TBL] [Abstract][Full Text] [Related]
3. The preliminary analysis of lymphatic flow around the connective tissues surrounding SMA and SpA elucidates patients' oncological condition in borderline-resectable pancreatic cancer.
Akita H; Asukai K; Mukai Y; Hasegawa S; Omori T; Miyata H; Ohue M; Sakon M; Wada H; Takahashi H
BMC Surg; 2024 Apr; 24(1):107. PubMed ID: 38614983
[TBL] [Abstract][Full Text] [Related]
4. Complete circumferential lymphadenectomy around the superior mesenteric artery with preservation of nerve plexus reduces locoregional recurrence after pancreatoduodenectomy for resectable pancreatic ductal adenocarcinoma.
Hirono S; Kawai M; Okada KI; Miyazawa M; Kitahata Y; Kobayashi R; Hayami S; Ueno M; Yamaue H
Eur J Surg Oncol; 2021 Oct; 47(10):2586-2594. PubMed ID: 34127329
[TBL] [Abstract][Full Text] [Related]
5. Long-term survival after resection of pancreatic ductal adenocarcinoma with para-aortic lymph node metastasis: case report.
Masui T; Kubota T; Aoki K; Nakanishi Y; Miyamoto T; Nagata J; Morino K; Fukugaki A; Takamura M; Sugimoto S; Onuma H; Tokuka A
World J Surg Oncol; 2013 Aug; 11(1):195. PubMed ID: 23945441
[TBL] [Abstract][Full Text] [Related]
6. Prognostic significance of the degree of lymphatic vessel invasion in locally advanced, surgically resectable pancreatic head cancer: A single center experience.
Morita K; Oshiro H; Mito K; Mieno MN; Tamba-Sakaguchi M; Niki T; Miki A; Koizumi M; Sakuma Y; Komatsubara T; Sata N; Fukushima N
Medicine (Baltimore); 2018 Dec; 97(49):e13466. PubMed ID: 30544433
[TBL] [Abstract][Full Text] [Related]
7. Prognostic implications of routine, immunohistochemical, and molecular staging in resectable pancreatic adenocarcinoma.
Niedergethmann M; Rexin M; Hildenbrand R; Knob S; Sturm JW; Richter A; Post S
Am J Surg Pathol; 2002 Dec; 26(12):1578-87. PubMed ID: 12459624
[TBL] [Abstract][Full Text] [Related]
8. MAPLE-PD trial (Mesenteric Approach vs. Conventional Approach for Pancreatic Cancer during Pancreaticoduodenectomy): study protocol for a multicenter randomized controlled trial of 354 patients with pancreatic ductal adenocarcinoma.
Hirono S; Kawai M; Okada KI; Fujii T; Sho M; Satoi S; Amano R; Eguchi H; Mataki Y; Nakamura M; Matsumoto I; Baba H; Tani M; Kawabata Y; Nagakawa Y; Yamada S; Murakami Y; Shimokawa T; Yamaue H
Trials; 2018 Nov; 19(1):613. PubMed ID: 30409152
[TBL] [Abstract][Full Text] [Related]
9. Prognostic Impact of Radiological Splenic Artery Involvement in Pancreatic Ductal Adenocarcinoma of the Body and Tail.
Kitamura K; Esaki M; Sone M; Sugawara S; Hiraoka N; Nara S; Ban D; Takamoto T; Mizui T; Shimada K
Ann Surg Oncol; 2022 Oct; 29(11):7047-7058. PubMed ID: 35691957
[TBL] [Abstract][Full Text] [Related]
10. Radiological tumour invasion of splenic artery or vein in patients with pancreatic body or tail adenocarcinoma and effect on recurrence and survival.
Kang JS; Choi YJ; Byun Y; Han Y; Kim JH; Lee JM; Sohn HJ; Kim H; Kwon W; Jang JY
Br J Surg; 2021 Dec; 109(1):105-113. PubMed ID: 34718433
[TBL] [Abstract][Full Text] [Related]
11. Radiographic Splenic Artery Involvement Is a Poor Prognostic Factor in Upfront Surgery for Patients with Resectable Pancreatic Body and Tail Cancer.
Kawai M; Hirono S; Okada KI; Miyazawa M; Kitahata Y; Kobayashi R; Ueno M; Hayami S; Yamaue H
Ann Surg Oncol; 2021 Mar; 28(3):1521-1532. PubMed ID: 32705517
[TBL] [Abstract][Full Text] [Related]
12. Optimal Lymphadenectomy of the Mesopancreas Based on Fluorescence Imaging During Pancreaticoduodenectomy.
Matsuki R; Sugiyama M; Kogure M; Yokoyama M; Nakazato T; Suzuki Y; Mori T; Abe N; Sakamoto Y
J Gastrointest Surg; 2021 May; 25(5):1241-1246. PubMed ID: 32462494
[TBL] [Abstract][Full Text] [Related]
13. Impact of resection margin status on recurrence and survival in pancreatic cancer surgery.
Tummers WS; Groen JV; Sibinga Mulder BG; Farina-Sarasqueta A; Morreau J; Putter H; van de Velde CJ; Vahrmeijer AL; Bonsing BA; Mieog JS; Swijnenburg RJ
Br J Surg; 2019 Jul; 106(8):1055-1065. PubMed ID: 30883699
[TBL] [Abstract][Full Text] [Related]
14. Mesenteric approach during pancreaticoduodenectomy for pancreatic ductal adenocarcinoma.
Hirono S; Kawai M; Okada KI; Miyazawa M; Shimizu A; Kitahata Y; Ueno M; Shimokawa T; Nakao A; Yamaue H
Ann Gastroenterol Surg; 2017 Sep; 1(3):208-218. PubMed ID: 29863125
[TBL] [Abstract][Full Text] [Related]
15. Cancer statistics, 2018.
Siegel RL; Miller KD; Jemal A
CA Cancer J Clin; 2018 Jan; 68(1):7-30. PubMed ID: 29313949
[TBL] [Abstract][Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
